ISDA

Deposition Date 2016-05-06

Release Date 2016-08-31

Last Version Date 2024-03-06

Entry Detail

PDB ID:

5JRS

Keywords:

TRANSFERASE/TRANSFERASE inhibitor

Title:

CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -3,4-DIHYDROQUINAZOLIN-3-YL)PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.97 Å

R-Value Free:

0.22

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase BTK
Gene (Uniprot):BTK
Chain IDs:A, B
Chain Length:267
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q06187 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

6MV

Primary Citation

Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).

De Lucca, G.V, Shi, Q, Liu, Q, Batt, D.G, Beaudoin Bertrand, M, Rampulla, R, Mathur, A, Discenza, L, D'Arienzo, C, Dai, J, Obermeier, M, Vickery, R, Zhang, Y, Yang, Z, Marathe, P, Tebben, A.J, Muckelbauer, J.K, Chang, C.J, Zhang, H, Gillooly, K, Taylor, T, Pattoli, M.A, Skala, S, Kukral, D.W, McIntyre, K.W, Salter-Cid, L, Fura, A, Burke, J.R, Barrish, J.C, Carter, P.H, Tino, J.A.Show

J.Med.Chem. 59 7915 7935 (2016)

PMID: 27531604 DOI: 10.1021/acs.jmedchem.6b00722

Abstact

Bruton's tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a critical role in multiple cell types responsible for numerous autoimmune diseases. This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK. With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clinical development.

Legend

Protein

Chemical

Disease

Primary Citation of related structures